Others titles

  • OECD Patients Survival And Mortality Related Quality Indicators
  • Patients Survival And Mortality In OECD Countries

Keywords

  • OECD Health Care Quality Indicators
  • OECD Health Care Performance Indicators
  • Deaths Among Patients
  • Cancer 5 Year Survival
  • Mental Disorders And Suicide Rate
  • Excess Of Mortality
  • Acute Myocardial Infarction Case Fatalities
  • Stroke Case Fatalities
  • In Patient Mortality
  • In Patient Deaths

OECD Patients Mortality And Survival Indicators

This dataset contains internationally comparable indicators regarding patients mortality and survival for country members and partners of OECD (The Organization for Economic Co-operation and Development) and for countries in accession negotiations with OECD. The indicators values cover the period 2000-2015.

Log in to download
Complexity

Get The Data

For getting access to data download links please read and accept the end-user license agreement.
Your Data License
  • Research
    Non-Commercial, Share-Alike, Attribution Free Forever
  • Commercial
    Commercial Use, Remix & Adapt, White Label Log in to download

John Snow Labs Standard End User License Agreement

Last updated:January 20, 2021

This Data Library End User License Agreement (“EULA”) applies to academic researchers, educators, and students using any product of John Snow Labs in John Snow Labs’ Data Library as defined below (hereinafter referred to “you”). This EULA is between you and John Snow Labs Inc., a Delaware corporation (“John Snow Labs”, “we” or “us”).

By downloading and/or using (as applicable) Data Library of John Snow Labs (as defined below), you automatically agree to be bound by, and use it in compliance with, this EULA. This EULA, together with additional terms and conditions and/or policies referenced herein or located on https://www.johnsnowlabs.com and/or conveyed to you by John Snow Labs, is a legally binding contract between you and John Snow Labs.

PLEASE READ THIS EULA CAREFULLY BEFORE DOWNLOADING OR USING DATA LIBRARY.

We may make changes to this EULA from time to time. When we do so, we will revise the “last updated” date given above. The then-current version of this EULA will supersede all earlier versions. You agree that your continued use of Data Library after such changes have been published to our EULA will constitute your acceptance of such revised EULA.

Definitions

“Data Library” means a data library provided by John Snow Labs and located at https://www.johnsnowlabs.com/marketplace/;

“Website” means https://www.johnsnowlabs.com being owned and operated by John Snow Labs.

Important Notice

By downloading and using any product from the Data Library, you acknowledge that the use of Data Library can be subject to the restrictions and controls imposed by United States export regulations.

You represent and warrant that you do not intend to use Data Library for any purpose prohibited by United States export regulations, including, without limitation, terrorism, cyber-attacks, cyber-crimes, money-laundering, industrial espionage, or nuclear, chemical or biological weapons proliferation. Further, you represent and warrant that you are not listed as a denied party on any list governing United States exports.

Eligibility

Our Data Library can be used by an individual.

In the event you have entered into a separate written agreement with John Snow Labs regarding Data Library that contemplates terms that are inconsistent with this EULA, the written agreement shall control and this EULA will not apply to you to the extent inconsistent with such written agreement, or, if such written agreement is contemplated to be in lieu of this EULA, then this EULA shall not apply at all

License Granted

Subject to your compliance with this EULA, as well as any other applicable policies, John Snow Labs grants you non-exclusive, non-transferable, revocable, license to download, access to, modify, and use of, Data Library worldwide (subject to applicable export laws) during the term of this EULA (as described below) under the following conditions:

  • The license can be used solely for research, private study and personal use of Data Library for unlimited period, or unless terminated under this EULA.were made;
  • This license is personal to you and is limited by all terms and conditions set forth in this EULA;
  • The license is granted as a non-commercial, attribution, share-alike and no-derivate-work license as more detailed below;
  • Under the attribution license, you must give the appropriate name of the creator and a copyright notice of John Snow Labs, provide link to this license and indicate if changes
  • Under the share-alike license, you can distribute modified works only under a license identical to this EULA;
  • Under the no-derivate-work license, you can perform only verbatim copies of Data Library, not derivate works or remixes based on it;
  • If the license is used for academic research purpose, the publication shall be made under the open-access, open-source and open-data license.

You can download any dataset from the Data Library from the Website.

Except for your pre-existing rights and this license granted to you, we and our licensors retain all rights, titles and interests in and to our Data Library, all related intellectual property rights, including trademarks (whether registered or pending), domain and business names. Our Data Library is protected by applicable intellectual property laws, including United States copyright law and international treaties.

John Snow Labs is entitled to revoke the license granted at any time at its sole discretion.

License Restrictions

You will be deemed to have taken any action that you permit, assist or facilitate any person or entity to take related to this EULA, your content or use of Data Library. You are responsible for end users’ use of your content and Data Library. You will ensure that all end users comply with your obligations under this EULA and that the terms of your agreement with each end user are consistent with this EULA. If you become aware of any violation of your obligations under this EULA caused by an end user, you will immediately suspend access to your content and Data Library by such end user.

License Restrictions

You will access or use our Data Library solely via John Snow Labs’ Data Library.

Except as otherwise explicitly provided in this EULA or as may be expressly permitted by applicable law, you will not, and will not permit or authorize any third party to:

  1. you cannot reproduce, translate, enhance, decompile, disassemble, reverse engineer or create derivative works of Data Library or its technological features or measures;
  2. you cannot rent, lease, sell, resell, loan, distribute, or sublicense access to any of Data Library;
  3. you cannot circumvent or disable any security or technological features or measures of Data Library;
  4. you cannot use our intellectual property rights without our express prior written authorization or in violation of this EULA;
  5. you cannot use Data Library with an intent to build a competitive product or service, or copy or substantially copy any ideas, features, functions, organization, structure, application program interface, graphics, or user interface of Data Library;
  6. you cannot copy, distribute, or resell any of the information; audio, visual, and audiovisual works, or other content made available on Data Library (collectively, “Content”) or compile or collect any Content as part of a database or other work;
  7. you cannot use any automated tool (e.g., robots, spiders) to access or use Data Library, or to store, copy, modify, distribute, or resell any Content;
  8. you cannot circumvent or disable any rights management, usage rules, or other security features of Data Library;
  9. you cannot use Data Library in a manner that overburdens, or that threatens the integrity, performance, or availability of, Data Library; or
  10. you cannot remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of Data Library or any Content.

If you breach any of this EULA, the above license will terminate automatically.

Fees and Taxes

This license is for non-commercial use. If you wish to use our Data Library for commercial use, please contact us at support@JohnSnowLabs.com.

Support and Updates

Under this EULA, support services are excluded.

From time to time John Snow Labs can perform updates to our software. If available, such updates may include bug fixes, new features and/or enhancements. You are solely responsible for deploying such updates at your own risk and liability.

Term and Termination

This EULA will become effective as of the date of your order of Data Library and shall be in effect until terminated.

John Snow Labs may suspend or terminate your right to use Data Library, if you or your end user’s use of Data Library:

  1. is in breach of this EULA;
  2. poses a security risk to Data Library;
  3. could adversely impact our systems, Data Library or other customers;
  4. could subject us, our affiliates, or any third party to liability; or
  5. could be fraudulent.

We may also suspend or terminate your right to use Data Library, if you have ceased to operate in the ordinary course, made an assignment for the benefit of creditors or similar disposition of your assets, or become the subject of any bankruptcy, reorganization, liquidation, dissolution or similar proceeding.

You will cease use of Data Library during any period of suspension, or upon termination of this EULA.

All provisions which by their nature are intended to survive termination shall survive termination of this EULA.

Access to Data Library

We do not provide you with the equipment to access Data Library. You are responsible for all fees charged by third parties related to your access and use of Data Library (e.g., charges by Internet service providers).

You are responsible for monitoring your use of Data Library, including payment of all fees and/or taxes related to such access and use. You agree that John Snow Labs is permitted to request and you hereby consent to provide John Snow Labs information related to your use of Data Library for auditing purposes.

You also certify that you are legally permitted to use Data Library, and take full responsibility for the selection and use of Data Library. This EULA is void where prohibited by law, and the right to use Data Library is revoked in such jurisdictions. John Snow Labs makes no claim that Data Library may be lawfully used outside of the United States. If you use Data Library from outside of the United States, you do so at your own risk and you are responsible for compliance with the laws of jurisdiction.

Privacy Policy

We may collect, store and receive personal and other information about you through our Products. Our collection and use of this information is governed by our Privacy Policy available at https://www.JohnSnowLabs.com/privacy/ which may be amended from time to time.

Links and Third Party Content

Data Library may display, or contain links to, third party products, services, and websites. Any opinions, advice, statements, services, offers, or other information that constitutes part of the content expressed, authored, or made available by other users or other third parties, or which is accessible through or may be located using Data Library (collectively, “Third Party Content”) are those of the respective authors or producers and not of us or our shareholders, directors, officers, employees, agents, or representatives.

We do not control Third Party Content and do not guarantee the accuracy, integrity or quality of such Third Party Content. We are not responsible for the performance of, we do not endorse, and we are not responsible or liable for, any Third Party Content or any information or materials advertised in any Third Party Content. By using Data Library, you may be exposed to content that is offensive, indecent, or objectionable. We are not responsible or liable, directly or indirectly, for any damage or loss caused to you by your use of or reliance on any goods, services, or information available on or through any third party service or Third Party Content. It is your responsibility to evaluate the information, opinion, advice, or other content available on and through our Products.

Proprietary Rights

John Snow Labs will not obtain any rights under this EULA from you (or your licensors) to your content.

Data Library is and remains the exclusive property of John Snow Labs and its licensors. Except for the access and use rights expressly set forth in this EULA, no license or other rights in or to Data Library or John Snow Labs trademark(s) and other intellectual property rights therein, are granted to you, and all such licenses and rights are expressly reserved. You will not remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of Data Library or any Content.

Trademarks

“John Snow Labs,” the John Snow Labs logo, and any other product, business or service name or slogan, whether registered or pending, displayed on Data Library are trademarks of John Snow Labs, Inc. or its suppliers or licensors, and may not be copied, imitated or used, in whole or in part, without the prior written permission of John Snow Labs or the applicable trademark holder. You may not use any metatags or any other “hidden text” utilizing “John Snow Labs” or any other name, trademark or product, business or service name of John Snow Labs without our prior written permission. In addition, the look and feel of Data Library, including all page headers, custom graphics, button icons and scripts, is the service mark, trademark and/or trade dress of John Snow Labs may not be copied, imitated or used, in whole or in part, without our prior written permission. All other trademarks, pending trademarks, registered trademarks, product names and company names or logos mentioned in Data Library are the property of John Snow Labs Inc. and/or their respective owners. Reference to any products, services, processes or other information, by trade name, trademark, manufacturer, supplier, or otherwise does not constitute or imply endorsement, sponsorship, or recommendation thereof by us.

Disclaimer of Warranties

YOUR USE OF DATA LIBRARY IS AT YOUR SOLE RISK. THE PRODUCTS AND CONTENT EACH ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS. WE AND OUR SUPPLIERS AND LICENSORS EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND NON-INFRINGEMENT. WE DO NOT GUARANTEE THE ACCURACY, COMPLETENESS, OR USEFULNESS OF THE PRODUCTS OR ANY CONTENT, AND YOU RELY ON THE PRODUCTS AND CONTENT AT YOUR OWN RISK. ANY MATERIAL THAT YOU ACCESS OR OBTAIN THROUGH OUR PRODUCTS IS DONE AT YOUR OWN DISCRETION AND RISK AND YOU WILL BE SOLELY RESPONSIBLE FOR ANY DAMAGE TO YOUR COMPUTER OR LOSS OF DATA THAT RESULTS FROM THE DOWNLOAD OF ANY MATERIAL THROUGH OUR PRODUCTS. NO ADVICE OR INFORMATION, WHETHER ORAL OR WRITTEN, OBTAINED BY YOU FROM US OR THROUGH OR FROM OUR PRODUCTS WILL CREATE ANY WARRANTY NOT EXPRESSLY STATED IN THIS EULA. SOME STATES MAY PROHIBIT A DISCLAIMER OF WARRANTIES AND YOU MAY HAVE OTHER RIGHTS THAT VARY FROM STATE TO STATE.

Limitation of Liability

WE AND OUR SUPPLIERS AND LICENSORS WILL NOT BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR EXEMPLARY DAMAGES, INCLUDING BUT NOT LIMITED TO, DAMAGES FOR LOSS OF PROFITS, GOODWILL, USE, DATA, OR OTHER INTANGIBLE LOSSES (EVEN IF WE HAVE BEEN ADVISED OF THE POSSIBILITY OF THESE DAMAGES), RESULTING FROM YOUR USE OF OUR PRODUCTS AND CONTENT. UNDER NO CIRCUMSTANCES WILL THE TOTAL LIABILITY OF US AND OUR SUPPLIERS AND LICENSORS OF ALL KINDS ARISING OUT OF OR RELATED TO YOUR USE OF THE PRODUCTS AND CONTENT (INCLUDING BUT NOT LIMITED TO WARRANTY CLAIMS), REGARDLESS OF THE FORUM AND REGARDLESS OF WHETHER ANY ACTION OR CLAIM IS BASED ON CONTRACT, TORT, OR OTHERWISE, EXCEED THE AMOUNTS, IF ANY, THAT YOU HAVE PAID FOR YOUR USE OF THE PRODUCTS AND CONTENT. BECAUSE SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF LIABILITY FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES, THE ABOVE LIMITATION MAY NOT APPLY TO YOU.

Indemnity

To the full extent permitted by applicable law, you shall defend, indemnify and hold harmless John Snow Labs, its affiliates and its licensors, and each of their respective employees, officers, directors, and representatives from and against any claims, damages, losses, liabilities, costs, and expenses (including reasonable attorney’s fees) arising out of or relating to any third party claim concerning: (a) your use of Data Library; (b) breach of this EULA or violation of applicable law by you; (c) any content or the combination of such content with other software, content or processes, including any claim involving alleged infringement or misappropriation of third-party rights by such content or combination; or (d) breach of any obligation or duty you owe to a third party.

Legal Notices

Enforcement of this EULA will be governed by the laws of the State of Delaware, excluding its conflict and choice of law principles. The exclusive jurisdiction and venue for any claims arising out of or related to this EULA or your use of Data Library will lie in the state and federal courts located in Sussex County, within the State of Delaware, and you irrevocably agree to submit to the jurisdiction of such courts. Our failure to enforce any right or provision in this EULA will not constitute a waiver of such right or provision unless acknowledged and agreed by us in writing. In the event that a court of competent jurisdiction finds any provision of this EULA to be illegal, invalid, or unenforceable, the remaining provisions will remain in full force and effect.

Notifications

We may use your contact information to notify you if we have any legitimate interest or if we need to notify you on any important information related to your use of Data Library. We will not send you newsletters unless you expressly consented to such notifications.

Contacting Us

If you have any questions or concerns about Data Library or this EULA, you may contact us by email at support@JohnSnowLabs.com.

Description

The OECD (The Organization for Economic Co-operation and Development) mission is to promote policies that will improve the economic and social well-being of people around the world. OECD’s work is based on continued monitoring of events in member countries as well as outside OECD area, and includes regular projections of short and medium-term economic developments. The OECD Secretariat collects and analyses data, after which committees discuss policy regarding this information, the Council makes decisions, and then governments implement recommendations. The OECD Health Datasets offers the most comprehensive source of comparable statistics on health and health systems across OECD countries. It is an essential tool to carry out comparative analyses and draw lessons from international comparisons of diverse health systems.

In order to monitor changes in cancer incidence and the quality of care, many countries have developed cancer registries that can analyze and report cancer survival at the national and regional levels. At the international level, a growing number of countries now participate in the global effort to monitor and publish robustly comparable cancer survival estimates via the CONCORD program for the Global Surveillance of Cancer Survival, led by the London School of Hygiene and Tropical Medicine. The OECD collaborates with the CONCORD program to strengthen countries’ capacity in monitoring the effectiveness of their health systems in delivering high-quality cancer care. The OECD’s Health Care Indicators for cancer care currently include the following indicators provided by the CONCORD program:

– Breast cancer 5-year net survival
– Cervical cancer 5-year net survival
– Colorectal cancer 5-year net survival
– Acute lymphoblastic leukaemia

Breast cancer 5-year net survival is measured by dividing the number of women aged 15-99 diagnosed with breast cancer (first primary cancer at the specified site) divided by the expected survival of a comparable group from the general population.

Cervical cancer 5-year net survival is measured by women aged 15-99 diagnosed with cervical cancer (first primary cancer at the specified site) divided by the expected survival of a comparable group from the general population.

Colorectal cancer 5-year net survival is measured by dividing the number of men and women aged 15-99 diagnosed with colorectal cancer (first primary cancer at the specified site) divided by the expected survival of a comparable group from the general population. Data is provided separately for colon and rectal categories of cancers.

Leukaemia is the most common childhood cancer and accounts for over 30% of all cancers diagnosed in children aged below 15 years old in the world (IARC, 2012). Children with acute leukaemia who are free of the disease for 5 years are considered to have been cured as remission after 5 years is rare.

The acute hospital care remains central to the performance of the health care system. Despite substantial gains in the sector, health care providers, researchers and policy makers continue to seek further improvements in the delivery of acute care. As part of these efforts, many countries have developed indicators to measure and monitor acute care performance. Such national efforts have been translated to the international stage through the use of a structured review process whereby expert panels have evaluated and recommended indicators related to cardiac care and acute care. The following three acute care indicators, developed through the HCQI (Health Care Quality Indicators) project, were considered suitable for international comparison:

– The rates of death within 30 days following hospital admissions for acute myocardial infarction (AMI)
– The rates of death within 30 days following hospital admissions for ischemic stroke
– The rates of death within 30 days following hospital admissions for hemorrhagic stroke

For the AMI and stroke indicators, two types of case-fatality indicators are collected. The first reports on the percentage of deaths that occur within 30 days following admission (admission-based), where the death occurred in the same hospital as the initial admission. The second indicator reports on the percentage of deaths that occur within 30 days following admission (patient-based), where the death may have occurred in any hospital or out of hospital. While the second indicator is preferred, not all countries have the capacity to report these data.

The admission-based AMI and stroke indicators are measured by dividing the number of deaths in the same hospital that occurred within 30 days of eligible hospital admission (as defined by the ICD-10 codes and age 45 years and older) by the number of admissions to hospital with primary diagnosis defined by the ICD-10 codes specified and age of 45 years and older, where the admission did not result in a transfer to another acute care hospital, from 1st of January to 31st of December in the specified year.

The patient-based AMI and stroke indicators are measured by dividing the number of deaths in any hospital and out of hospital that occurred within 30 days of eligible hospital admission (as defined by the ICD-10 codes and age 45 years and older) by the number of admissions to hospital with primary diagnosis eligible defined by the ICD-10 codes specified and age of 45 years and older, from 1st of January to 31st December in the specified year.

The HCQI project has identified mental health care as a priority area for further quality of care indicator development, to build on the existing indicators relating to health workforce (e.g. psychiatrists) and health status (e.g. suicide). Through the use of a structured review process, expert panels have previously evaluated and recommended indicators related to quality of mental health care for further consideration. A survey of countries participating in this aspect of the HCQI project subsequently revealed that systems of care vary markedly across countries and the availability of national indicator data suitable for international comparison is limited at this time. The following indicators, developed through the HCQI project, are currently considered suitable for international comparison:

– In-patient suicides among people diagnosed with a mental disorder
– Suicide within 1 year after discharge among patients diagnosed with a mental disorder
– Suicide within 30 days after discharge among patients diagnosed with a mental disorder
– Excess mortality for patients diagnosed with schizophrenia
– Excess mortality for patients diagnosed with severe mental illness
– Excess mortality for patients diagnosed with bipolar disorder

The HCQI project has monitored national information system infrastructures with a view to refine definitions of these indicators and to improve cross-national comparability.

In-patient suicides among people diagnosed with a mental disorder is measured for patients aged 15 and older by dividing the number of patient discharges among denominator cases coded as suicide in the reference year by the number of patients discharged with a principal diagnosis or first two listed secondary diagnosis code of mental health and behavioral disorders in the reference year.

Suicide within 1 year after discharge among patients diagnosed with a mental disorder is measured for patients aged 15 and older by dividing the number of patients among denominator cases that committed suicide within 1 year after discharge by the number of patients discharged alive with a principal diagnosis or first two listed secondary diagnosis code of mental health and behavioral disorders in the reference year. In cases with several admissions during the reference year, the follow up period starts from the last discharge (discharge from a hospital and thus not from one department to another). This indicator required data that links hospital records with deaths after discharge.

Suicide within 30 days after discharge among patients diagnosed with a mental disorder is measured for patients aged 15 and older by dividing the number of patients among denominator cases that committed suicide within 30 days after discharge by the number of patients discharged alive with a principal diagnosis or first two listed secondary diagnosis code of mental health and behavioral disorders in the reference year. In cases with several admissions during the reference year, the follow up period starts from the last discharge (discharge from a hospital and thus not from one department to another).

Excess mortality for patients diagnosed with schizophrenia is measured for patients aged 15-74 years and older as the ratio of two mortality rates:

– Age- and sex-standardized of all deaths and for all persons aged between 15 and 74 in the reference year among all people aged 15-74 ever diagnosed with schizophrenia (with the specified ICD-10 codes) as obtained from a register or equivalent data source in the reference year
– Age- and sex-standardized of all deaths and for all persons aged between 15 and 74 in the reference year among all people aged 15-74 in the reference year

Excess mortality for patients diagnosed with severe mental illness is measured for patients aged 15-74 years and older as the ratio of two mortality rates:

– Age- and sex-standardized of all deaths and for all persons aged between 15 and 74 in the reference year among all people aged 15-74 ever diagnosed with severe mental illness as obtained from a register or equivalent data source in the reference year
– Age- and sex-standardized of all deaths and for all persons aged between 15 and 74 in the reference year among all people aged 15-74 in the reference year

Only the countries with a pre-existing registry which records the whole population of severe mental illnesses needed to report this indicator.

Excess mortality for patients diagnosed with bipolar disorder is measured for patients aged 15-74 years and older as the ratio of two mortality rates:

– Age- and sex-standardized of all deaths and for all persons aged between 15 and 74 in the reference year among all people aged 15-74 ever diagnosed with bipolar disorder (with the specified ICD-10 codes) as obtained from a register or equivalent data source in the reference year
– Age- and sex-standardized of all deaths and for all persons aged between 15 and 74 in the reference year among all people aged 15-74 in the reference year

Breaks in the time-related continuity of data on which the indicators values are based are specified in the content of dataset. There are also specified the cases were the methodology used for data collection was different (deviations exist).

About this Dataset

Data Info

Date Created

2017-11-10

Last Modified

2017-11-10

Version

2017-11-10

Update Frequency

Irregular

Temporal Coverage

2000-2015

Spatial Coverage

OECD Members and Partners Countries

Source

John Snow Labs; The Organization for Economic Co-operation and Development;

Source License URL

Source License Requirements

N/A

Source Citation

N/A

Keywords

OECD Health Care Quality Indicators, OECD Health Care Performance Indicators, Deaths Among Patients, Cancer 5 Year Survival, Mental Disorders And Suicide Rate, Excess Of Mortality, Acute Myocardial Infarction Case Fatalities, Stroke Case Fatalities, In Patient Mortality, In Patient Deaths

Other Titles

OECD Patients Survival And Mortality Related Quality Indicators, Patients Survival And Mortality In OECD Countries

Data Fields

Name Description Type Constraints
Data_Year_Or_Survival_1st_YearThe year corresponding to the specified indicator value for a country and population group or the first year of the 5 year survival time corresponding to the specified indicator value for a country and population groupdaterequired : 1
Survival_5th_YearThe fifth year of the 5 year survival time corresponding to the specified indicator value for a country and population groupdate-
CountryThe name of the country member or partner of OECD or in accession negotiations with OECDstringrequired : 1
Country_AbbreviationThe abbreviated name of the country member or partner of OECD or in accession negotiations with OECDstringrequired : 1
Country_StatusSpecifies whether the country is member or partner of OECD or has an accession agreement with OECDstringenum : Array ( [0] => OECD member [1] => OECD partner [2] => Accession agreement ) required : 1
Indicator_CategorySpecifies a group of indicators related to the patients survival or mortalitystringenum : Array ( [0] => 5-year survival - Cancer [1] => Excess of mortality - Mental health disorders/diseases [2] => Suicide risk - Mental health disorders [3] => Mortality after admission - Cardio-vascular diseases ) required : 1
IndicatorSpecifies the indicator related to the patients survival or mortalitystringrequired : 1
Measurement_MethodDescribes how the indicator is measuredstringrequired : 1
Disease_ICD_10_CodesSpecifies the disease codes described in the indicator measurement methodologystring-
GenderSpecifies the gender of the demographic group for which the indicator is measuredstringenum : Array ( [0] => Males [1] => Females [2] => Both genders ) required : 1
AgeSpecifies the age of the demographic group for which the indicator is measuredstringenum : Array ( [0] => 0-14 years [1] => 15 years and over [2] => 45 years and over [3] => 15-74 years ) required : 1
Indicator_ValueThe estimated value of the indicator for the specified population group, year and countrynumberlevel : Ratio
Upper_Value_95_Confidence_LevelThe upper value of the 95% confidence interval of the estimated value of the indicatornumberlevel : Ratio
Lower_Value_95_Confidence_LevelThe lower value of the 95% confidence interval of the estimated value of the indicatornumberlevel : Ratio
Additional_NotesAdditional information related to the indicator value or measurementstring-

Data Preview

Data_Year_Or_Survival_1st_YearSurvival_5th_YearCountryCountry_AbbreviationCountry_StatusIndicator_CategoryIndicatorMeasurement_MethodDisease_ICD_10_CodesGenderAgeIndicator_ValueUpper_Value_95_Confidence_LevelLower_Value_95_Confidence_LevelAdditional_Notes
20102014IsraelISROECD member5-year survival - CancerBreast cancer five year net survivalAge adjusted percent of survivorsC50.0-50.9Females15 years and over888987
20102014ItalyITAOECD member5-year survival - CancerBreast cancer five year net survivalAge adjusted percent of survivorsC50.0-50.9Females15 years and over8686.485.5
20002004TurkeyTUROECD member5-year survival - CancerBreast cancer five year net survivalAge adjusted percent of survivorsC50.0-50.9Females15 years and over84.88881.5
20102014FranceFRAOECD member5-year survival - CancerBreast cancer five year net survivalAge adjusted percent of survivorsC50.0-50.9Females15 years and over86.78885.5
20102014PolandPOLOECD member5-year survival - CancerBreast cancer five year net survivalAge adjusted percent of survivorsC50.0-50.9Females15 years and over76.57776.1
20002004BelgiumBELOECD member5-year survival - CancerBreast cancer five year net survivalAge adjusted percent of survivorsC50.0-50.9Females15 years and over84.88683.5
20002004ChileCHLOECD member5-year survival - CancerBreast cancer five year net survivalAge adjusted percent of survivorsC50.0-50.9Females15 years and over74.681.168.2
20002004ItalyITAOECD member5-year survival - CancerBreast cancer five year net survivalAge adjusted percent of survivorsC50.0-50.9Females15 years and over84.284.583.8
20002004JapanJPNOECD member5-year survival - CancerBreast cancer five year net survivalAge adjusted percent of survivorsC50.0-50.9Females15 years and over85.986.685.2
20002004KoreaKOROECD member5-year survival - CancerBreast cancer five year net survivalAge adjusted percent of survivorsC50.0-50.9Females15 years and over79.280.777.7